In Segment A, individuals will get different doses and schedules of oral ABBV-744 pill to detect Risk-free dosing regimen. More contributors is going to be enrolled at the recognized monotherapy dosign routine. In Section B, members will get oral ruxolitinib and ABBV-744 will probably be offered as "incorporate-on" therapy. In https://abbv-744cancertreatmentcl91345.blogcudinti.com/32061315/considerations-to-know-about-abbv-744-brd4-inhibitor-cancer-therapy-efficacy